WEIGHT & METABOLIC RESEARCH
A dual-agonist peptide activating both GIP and GLP-1 pathways, studied for appetite, glucose regulation, and body composition.
Tirzepatide is a dual-agonist peptide that activates both the GIP and GLP-1 receptor pathways. It is studied for appetite signaling, glucose regulation, insulin sensitivity, and body-composition outcomes, and is an FDA-approved medication in its clinical formulations.
Included because it combines FDA-approved human evidence with a well-mapped dual-receptor mechanism and broad, consistent clinical and research use. It anchors the established end of the metabolic-research spectrum.
Activates GLP-1 receptors to reduce appetite and slow gastric emptying.
Activates GIP receptors to support insulin response and metabolic signaling.
Together these help regulate food intake, post-meal glucose handling, and energy balance.
WHAT THE RESEARCH MEASURED
Findings describe study outcomes, not expected personal results.
Tirzepatide is FDA-approved in its clinical formulations. Material offered here is sold and offered strictly for laboratory and research use and is not a medicine.
